M. Cefalì

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab

L. Mazzucchelli, F. Molinari, M. Frattini, 2021, Oncotarget.

Asymptomatic versus symptomatic pulmonary embolism in oncologic patients: Does clinical presentation influence outcome?

A. Riccardi, V. Fregoni, L. Pavesi, 2017 .

Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis.

Dylan Mangan, M. Cefalì, Caroline-Claudia Erhart, 2024, Swiss medical weekly.

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

M. Frattini, L. Wannesson, P. Froesch, 2022, Cancers.

Lymphocyte count and lymphocyte-to-white blood cells ratio as indicators of survival in specific cancer subtypes.

P. Saletti, M. Cefalì, S. De Dosso, 2019, International immunopharmacology.

Research progress on KRAS mutations in colorectal cancer

M. Frattini, S. Dosso, S. Epistolio, 2021 .

Treatment Options in BRAF-mutant Metastatic Colorectal Cancer

S. Dosso, M. Cefalì, M. C. Palmarocchi, 2022, Oncology & Haematology.